Compare TKC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | LNTH |
|---|---|---|
| Founded | 1993 | 1956 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.6B |
| IPO Year | 2001 | 2014 |
| Metric | TKC | LNTH |
|---|---|---|
| Price | $5.95 | $93.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $87.00 |
| AVG Volume (30 Days) | 678.4K | ★ 833.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $31.20 | N/A |
| Revenue Next Year | $24.27 | $14.19 |
| P/E Ratio | ★ $26.98 | $52.26 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $5.35 | $47.27 |
| 52 Week High | $7.18 | $98.27 |
| Indicator | TKC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 65.27 |
| Support Level | $5.89 | $72.35 |
| Resistance Level | $6.14 | N/A |
| Average True Range (ATR) | 0.11 | 3.24 |
| MACD | -0.05 | 0.47 |
| Stochastic Oscillator | 4.74 | 73.41 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.